ג'קאבי 5 מג ישראל - עברית - Ministry of Health

ג'קאבי 5 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

ג'קאבי 15 מג ישראל - עברית - Ministry of Health

ג'קאבי 15 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

ג'קאבי 20 מג ישראל - עברית - Ministry of Health

ג'קאבי 20 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 20 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

ג'קאבי 10 מג ישראל - עברית - Ministry of Health

ג'קאבי 10 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 10 mg - ruxolitinib